Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.58
- Piotroski Score 6.00
- Grade Buy
- Symbol (ACAD)
- Company ACADIA Pharmaceuticals Inc.
- Price $15.02
- Changes Percentage (2.74%)
- Change $0.4
- Day Low $14.41
- Day High $15.03
- Year High $32.59
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $26.00
- High Stock Price Target $62.00
- Low Stock Price Target $15.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.37
- Trailing P/E Ratio -40.24
- Forward P/E Ratio -40.24
- P/E Growth -40.24
- Net Income $-61,286,000
Income Statement
Quarterly
Annual
Latest News of ACAD
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Why quant giant D.E. Shaw seeks out academics, doctors, and veterans to work at the $60 billion hedge fund
After pursuing a career in academia, Tim Willenken shifted to corporate development at D.E. Shaw, a secretive hedge fund. The firm values diverse backgrounds and offers robust training. Its hiring pro...
By Business Insider | 12 hours ago -
Why More Academic Institutions Are Now Betting On The Trades
Traditional academic institutions are adapting to the rising demand for skilled trades. Vocational programs are gaining popularity due to lower costs and quicker career paths. Educational organization...
By Forbes | 2 days ago -
Army QB Bryson Daily out for service-academy game against Air Force
Daily, the quarterback for Army, will not start the next game. Junior Dewayne Coleman will take his place. Daily has led Army to a 7-0 record and is the FBS leader in rushing touchdowns....
By AP NEWS | 3 days ago
